Clinical Trials Logo

Hypoalbuminemia clinical trials

View clinical trials related to Hypoalbuminemia.

Filter by:

NCT ID: NCT06355479 Completed - Hepatic Cirrhosis Clinical Trials

A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia

Start date: April 10, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA. The main question it aims to answer is whether OsrHSA is effective in elevating the serum albumin level of cirrhotic patients with hypoalbuminemia. Researchers will compare OsrHSA to the positive comparator, plasma-derived HSA (pHSA) to see if OsrHSA presents as non-inferior to pHSA in the indication of hypoalbuminemia in hepatic cirrhosis patients. Participants will be randomized in a 1:1 ratio to receive OsrHSA or HpHSA (20g IV qd) for up to 14 days, following an EOT visit. Follow-up visits will be taken on EOT+7d, EOT+14d, and EOT+30d, respectively.

NCT ID: NCT06268314 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Feeding Pattern and Hypoalbuminemia in Pediatrics With Chronic Kidney Disease.

Start date: March 1, 2024
Phase:
Study type: Observational

To determine the impact of feeding pattern on the development of hypoalbuminemia and out come of pediatric patients with chronic kidney disease.

NCT ID: NCT05953961 Recruiting - Clinical trials for Carcinoma, Hepatocellular

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

REALM
Start date: August 8, 2023
Phase: N/A
Study type: Interventional

This clinical trial will compare 1-year outcomes in patients with hypoalbuminemia and a new diagnosis of small, early-stage hepatocellular carcinoma (HCC) who are candidates for both 90-Yittrium Therasphere transarterial radioembolization (90Y) and microwave ablation (MWA). The study will determine whether treatment with 90Y lowers the risk of disease progression within the first year after diagnosis. Participants will be randomized to receive either first cycle 90Y or MWA and then proceed with standard of care.

NCT ID: NCT05797649 Recruiting - Heart Failure Clinical Trials

Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis

Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).

NCT ID: NCT05050851 Not yet recruiting - Clinical trials for Anemia, Iron Deficiency

Nutritional Parameters and Other Risk Factors Affecting Severity of Pneumonia in Children Under Five Years in Upper Egypt

Start date: September 30, 2021
Phase:
Study type: Observational

Decrease mortality rate resulting from pneumonia

NCT ID: NCT04546958 Active, not recruiting - Clinical trials for End Stage Renal Disease on Dialysis

Nutritional Interventions in Peritoneal Dialysis Patients With Hypoalbuminemia

Start date: October 2, 2020
Phase: N/A
Study type: Interventional

Inadequate dietary protein intake is well-known cause of hypoalbuminemia in dialysis population. Protein loss into dialysate and increased catabolic state due to uremic milieu or inflammation worsened hypoalbuminemia, hence high protein diet is recommended in patients on peritoneal dialysis (PD). The recommendations from K/DOQI clinical practice guidelines for the amount of daily protein intake is based on expert opinion and the optimal daily protein intake in PD patients is not known. The investigators hypothesize that higher dietary protein intake has a greater beneficial effect on nutritional status in hypoalbuminemic PD patients. In particular, 1.5 g/kg protein intake provides a better beneficial effect than 1.2 g/kg protein intake.

NCT ID: NCT04071041 Terminated - Clinical trials for Community-acquired Pneumonia

Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.

ALBUCAP
Start date: October 31, 2019
Phase: Phase 3
Study type: Interventional

Community-acquired pneumonia (CAP) remains a leading cause of death world-wide. Hypoalbuminemia is associated with worse outcomes. However, whether albumin administration would have a beneficial effect in outcome in patients with CAP remains uncertain. This project proposes to test the hypothesis of whether the administration of albumin in hypoalbuminemic patients with CAP would increase the proportion of clinical stable patients at day 5.

NCT ID: NCT04046263 Completed - Hyperphosphatemia Clinical Trials

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

Start date: February 1, 2020
Phase: Phase 4
Study type: Interventional

Prospective pilot study to determine if changing the phosphate binder to sucroferric oxyhydroxide for for 6 months improves disordered mineral metabolism and nutrition status in peritoneal dialysis patients.

NCT ID: NCT04045366 Recruiting - Clinical trials for Critically Ill Patients

Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients

Start date: September 21, 2012
Phase:
Study type: Observational

This prospective study will explore the pharmacokinetic exposure and pharmacodynamics of the echinocandins (caspofungin or anidulafungin) in critically ill patients.

NCT ID: NCT03675906 Active, not recruiting - Clinical trials for Acute Kidney Failure

The Relationship Between Hypoalbuminemia and Development of Acute Kidney Failure (AKI) According to KDIGO Criteria

Start date: September 12, 2018
Phase:
Study type: Observational

This study was designed to determine the association between preoperative and postoperative hypoalbuminemia and AKI in older age hip fracture surgeons, to determine which period of hypoalbuminemia contributes more to AKI development, the incidence of AKI according to anesthesia type, the presence of other factors affecting AKI development, the duration of hospitalization and cost- to be investigated.